- Datum15.01.2025
- Uhrzeit15:00 - 15:30 Uhr
- Veranstalter
stock3
Thomas May
Moderator
Novo Nordisk AS Aktie
Verkaufen
Kaufen
Novo Nordisk AS Chart
stock3 TerminalDu willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen
Novo Nordisk AS Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (XETRA)
-19,73 %
Intraday
-20,54 %
1 Woche
-20,89 %
1 Monat
-14,82 %
Seit Jahresbeginn
-14,50 %
1 Jahr
65,25 %
3 Jahre
203,23 %
5 Jahre
344,14 %
10 Jahre
Wikifolio
Passender Service zu Novo Nordisk AS
Webinar zu Novo Nordisk AS
Kursinformationen (XETRA)
- Tagestief / Hoch (€)-
- 52W-Tief / Hoch (€)71,620-138,480
- Jahrestief / Hoch (€)71,620-138,480
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Novo Nordisk AS
| Ex-Datum | Fiskaljahr | Dividende | Rendite |
|---|---|---|---|
| - | 2027 (e) | ||
| - | 2026 (e) | ||
| - | 2025 (e) | ||
| 15.08.2024 | 2024 | 3,50 kr | 0,38 % |
| 22.03.2024 | 2023 | 6,40 kr | 0,71 % |
Termine von Novo Nordisk AS
- Feb5Novo Nordisk ASQ4 2024 Earnings Release
- Mai7Novo Nordisk ASQ1 2025 Earnings Release
- Aug6Novo Nordisk ASQ2 2025 Earnings Release
Beschreibung
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
